Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib, Cytarabine, and Dexamethasone in Relapsed/Refractory Mantle Cell Lymphoma
NCT02840539Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Oct 2016
- Primary completion
- Mar 2021
- Modality
- Modified Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, cytarabine, dexamethasone in mantle cell lymphoma (MCL), sponsored by Seoul National University Hospital. Started Oct 2016; status: completed.
02
Drugs
bortezomibcytarabinedexamethasone
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02840539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02840539.